<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275299</url>
  </required_header>
  <id_info>
    <org_study_id>Tranmod</org_study_id>
    <nct_id>NCT02275299</nct_id>
  </id_info>
  <brief_title>Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the efficacy and safety of Iguratimod Plus Methotrexate
      Compared to Leflunomid Plus Methotrexate in patients with active Rheumatoid Arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with ACR 20 response and Change in Disease Activity as measured by the DAS28</measure>
    <time_frame>week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in modified Total Sharp Score (mTSS)</measure>
    <time_frame>week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ACR 50 response and ACR70 response</measure>
    <time_frame>week 24,week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in number of swollen and tender joins, Erythrocyte sedimentation rate (ESR) ,C-reactive protein (CRP),anti-citrullinated-protein antibody (ACPA) and heumatoid factor(RF)</measure>
    <time_frame>week 24, week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve the ACR20, ACR50 and ACR70</measure>
    <time_frame>week 12, week 24, week 40, week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Simplified Disease Activity Index (SDAI) ≤ 3.3 and change from baseline in Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>week 12, week 24, week 40, week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Iguratimod and MTX combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid) Drug:MTX 2.5 mg/tablet, taken orally once a week, 4 tablets/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leflunomide and MTX combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid) Drug: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iguratimod</intervention_name>
    <description>Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks</description>
    <arm_group_label>Iguratimod and MTX combination</arm_group_label>
    <other_name>Iremod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide</intervention_name>
    <description>Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks</description>
    <arm_group_label>Leflunomide and MTX combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks</description>
    <arm_group_label>Iguratimod and MTX combination</arm_group_label>
    <arm_group_label>Leflunomide and MTX combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a diagnosis of RA according to the diagnostic criteria of the American
             College of Rheumatology (ACR) (revised in 1987)

          -  Rheumatoid Arthritis for more than 3 months from the time of the initial diagnosis

          -  Functional Class II-III

          -  Subjects have active RA at the time of screening

          -  Subjects with inadequate response to biologics should have a washout period before the
             initiation of study. For etanercept, washout period should be 2-week, and 8-week for
             infliximab and adalimumab.

          -  For firstly diagnostic RA patients, the disease activity should be moderate to severe,
             with DAS28&gt;3.2

          -  Must have at least 4 tender joints (66 join count) and 8 swollen joints( 68 join
             count) at screening and baseline

          -  Has a C-reactive protein ≥ 10 mg/L(or 1.0 mg/dL) OR Erythrocyte Sedimentation Rate
             (ESR) ≥ 28 mm/hr

          -  Must have a negative Pregnancy test and use adequate method of contraception
             throughout the trial

          -  Written informed consent

        Exclusion Criteria:

          -  Preceding treatment with DMARDs, immunosuppressants (cyclophosphamide, cyclosporine,
             azathioprine, etc.), or Tripterygium within 4 weeks prior to study entry

          -  Subjects have been treated with iguratimod or leflunomide combined with MTX before
             screening.

          -  Subjects combined with other autoimmune disease, such as systemic lupus erythematosus
             (SLE), mixed connective tissue disease (MCTD), scleriasis and polymyositis, except for
             Sjögren syndrome.

          -  Chest x-ray abnormalities, such as tuberculosis, interstitial pulmonary fibrosis, etc.

          -  ALT &gt;1.5×ULN, AST &gt;1.5×ULN, Cr &gt;135umol/L, total bilirubin&gt;1.5×ULN

          -  WBC&lt;4×109/L，HGB&lt;85g/L，PLT&lt;100×109/L

          -  Subjects with serious cardiovascular, renal, hematologic, endocrine diseases or
             malignant

          -  Women of Pregnant or breastfeeding, and male or female with recent plan to conception

          -  Subjects with immunodeficiency, uncontrolled infection and active gastrointestinal
             disease

          -  Allergic to any of the study drugs

          -  History of alcoholism

          -  Subjects with mental illness

          -  Subjects receiving live vaccines recently

          -  Subjects participating in other clinical study within 3 months prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>weihong zhao, doctor</last_name>
    <phone>+86(25) 8556 6666</phone>
    <phone_ext>8701</phone_ext>
    <email>zhaoweihong@simcere.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengchun Zhang, doctor</last_name>
      <phone>+86（10）6915 6114</phone>
      <email>zhangfccra@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

